ABOUT ASPEN

This year we celebrate our 20th anniversary as a JSE-listed company.

Established from humble beginnings in Durban, South Africa and with a 160 year heritage, we have grown into a leading specialty and branded multinational pharmaceutical company and we distribute our products to more than 150 countries.

Our extensive basket of high quality, affordable medicines and products treat a broad spectrum of acute and chronic conditions experienced through all stages of life.

RegionalOverviews

DEVELOPED EUROPE

SUB-SAHARAN AFRICA

AUSTRALASIA

LATIN AMERICA

DEVELOPING EUROPE & CIS

China

Japan

Other Asia

Middle East and North Africa

USA & Canada

DEVELOPED EUROPE

Our Developed Europe business is made up of operations in Europe’s major developed countries. The Anaesthetics and Thrombosis portfolios are the leading therapeutic focused brands in Developed Europe. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:0 – 2 yearsUSDnil

3 – 5 yearsUSDnil

SUB-SAHARAN AFRICA

The SSA business provides a diverse basket of branded, generic, OTC and consumer health products which are supplied to both the private and public sectors primarily in South Africa. Our presence outside of South Africa is mainly in Namibia, Botswana, Tanzania, Kenya, Nigeria, Ghana and Uganda.

IMS* value of pipeline as at 30 June 2018 anticipated to be launched in:0 – 2 yearsUSD119 million

3 – 5 yearsUSD250 million

*South Africa only, rest of SSA not covered by IMS.

Australasia

We supply a diversified portfolio of branded prescription, OTC, consumer and infant nutritional products into Australia and New Zealand. We are one of the largest manufacturers in Australia and our manufacturing site in Melbourne produces certain tablets, liquids and semisolids.

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:0 – 2 yearsUSD113 million

3 – 5 yearsUSD11 million

Latin America

We entered the Latin American market in 2008 and initially established a presence in Brazil, Mexico and Venezuela. We have expanded our coverage in this region and now also have a presence in Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina and offer a comprehensive product range that encompasses branded prescription and OTC products as well as infant nutritionals. Our Vallejo site in Mexico has the capability to manufacture infant nutritionals as well as pharmaceutical solids, semisolids and liquids.

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:0 – 2 yearsUSD4 million

3 – 5 yearsUSDnil

China

Aspen China is set to become a significant contributor to the Group performance with a product range comprising the recently acquired Thrombosis and Anaesthetic Brands as well as some smaller global brands.

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:0 – 2 yearsUSDnil

3 – 5 yearsUSD13 million

Japan

Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:0 – 2 yearsUSDnil

3 – 5 yearsUSDnil

Other Asia

Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 46% of revenue in these countries, followed by several products in the Regional Brands category. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia.

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:0 – 2 yearsUSD45 million

3 – 5 yearsUSD1 million

Middle East and North Africa

We supply globally branded pharmaceutical products as well as local brands into multiple territories within Middle East and North Africa (“MENA”). Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2018 financial year.

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:0 – 2 yearsUSD160 million

3 – 5 yearsUSD3 million

USA & Canada

Aspen Pharmacare Canada was founded in 2014 to support our products distributed in this region. The development of our complex API capabilities into niche FDF offerings represents an opportunity for future product launches in the United States. Our satellite API facility in Sioux City supports the Oss site in supplying APIs worldwide.